Cycle Pharmaceuticals Hauls In USD 25 Million In A Debt Financing Agreement Cycle Pharmaceuticals, a biotech company focusing exclusively on rare diseases, announced a strategic financing agreement worth USD25 million credit facility with Deutsche Bank AG. Headquartered in the UK, Cycle Pharmaceut...
Find MoreMerck’s Gefapixant could become the first drug approved for Chronic Cough ATS 2020 Virtual is happening from August 5 to August 10, and it is exciting to watch major Respiratory /Pulmonary Pharmaceutical companies and their key presentations. Merck is worth mentioning here, as it is presenting key posters and...
Find MoreWhat does a yellow ribbon signify? It symbolizes support for Sarcoma patients. Sarcoma – an umbrella term for several forms of cancer that occur in muscles or bones – is a rare form of cancer. There exist more than 70 types of sarcomas – mostly considered rare – classified on the basis of the type of tissue they af...
Find MoreFUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...
Find MoreGNA Biosolutions nets USD 13.5 Million in a Series C Funding GNA Biosolutions has secured USD 13.5 Million completing its all the rounds of financing. GNA Biosolutions GmbH, a Germany-based molecular diagnostics company has been able to successfully secure IVD-CE marking of its first point-of-care (POC) molecul...
Find MoreAI-powered drug-maker Recursion Pharmaceuticals secures USD 121 M to accelerate its clinical programs Recursion Pharmaceuticals, a next-gen biopharma company, has raised USD 121 Million in Series C financing. The Series C round was led by Baillie Gifford's flagship investment trust, Scottish Mortgage Investment...
Find MoreApollomics raises USD 100 Million for funding of transpacific cancer R&D plan Apollomics has raised USD 100 million for funding an oncology clinical trial program. The series B round sets Apollomics to progress its c-Met inhibitor and pipeline of other clinical-phase assets. OrbiMed Asia-backed Apo...
Find MoreAbbVie aims for best-in-class psoriasis prospect The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way. AbbVie prospect risankizumab showed it could bring 47% of patients to complete skin clearance by week 16 of treatment in a pha...
Find MoreBayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights’ platform- Be...
Find MoreHemophilia is the most common inherited bleeding disorder which leads to spontaneous bleeding as the blood does not clot properly. Hemophilia, characterized by the spontaneous bleeding and swollen joints due to bleeding into the joints, is of several different types- such as Hemophilia A, Hemophilia B, and...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.